MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference
Date: November 10, 2026
Presentation Time: 11:00 AM EST
Stifel 2026 Healthcare Conference
Date: November 11, 2026
Presentation Time: 4:00 PM EST
UBS Global Biopharma Conference
Date: November 17, 2026
Presentation Time: 4:00 PM GMT
Jefferies Global Healthcare Conference
Date: November 18, 2026
Presentation Time: 4:30 PM GMT
Webcasts and replays of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
